Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer
The emergence of immunotherapy has profoundly changed the treatment model for triple-negative breast cancer (TNBC). But the heterogeneity of this disease resulted in significant differences in immunotherapy efficacy, and only some patients are able to benefit from this therapeutic modality. With the...
Main Authors: | Yiwen Zheng, Shujin Li, Hongchao Tang, Xuli Meng, Qinghui Zheng |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1153990/full |
Similar Items
-
Advances in immunotherapy for triple-negative breast cancer
by: Yang Liu, et al.
Published: (2023-09-01) -
Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer
by: Peizhen Geng, et al.
Published: (2023-06-01) -
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
by: Jakub Wesolowski, et al.
Published: (2022-08-01) -
Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance
by: Chanjuan Zheng, et al.
Published: (2023-07-01) -
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
by: Liying Li, et al.
Published: (2023-01-01)